JP2009503093A5 - - Google Patents

Download PDF

Info

Publication number
JP2009503093A5
JP2009503093A5 JP2008525132A JP2008525132A JP2009503093A5 JP 2009503093 A5 JP2009503093 A5 JP 2009503093A5 JP 2008525132 A JP2008525132 A JP 2008525132A JP 2008525132 A JP2008525132 A JP 2008525132A JP 2009503093 A5 JP2009503093 A5 JP 2009503093A5
Authority
JP
Japan
Prior art keywords
insulin
composition
patient
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008525132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009503093A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/030014 external-priority patent/WO2007016600A2/en
Publication of JP2009503093A publication Critical patent/JP2009503093A/ja
Publication of JP2009503093A5 publication Critical patent/JP2009503093A5/ja
Pending legal-status Critical Current

Links

JP2008525132A 2005-08-01 2006-08-01 インスリン産生細胞の機能を保持する方法 Pending JP2009503093A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70429505P 2005-08-01 2005-08-01
PCT/US2006/030014 WO2007016600A2 (en) 2005-08-01 2006-08-01 Method of preserving the function of insulin-producing cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015002059A Division JP2015091854A (ja) 2005-08-01 2015-01-08 インスリン産生細胞の機能を保持する方法

Publications (2)

Publication Number Publication Date
JP2009503093A JP2009503093A (ja) 2009-01-29
JP2009503093A5 true JP2009503093A5 (enExample) 2009-09-03

Family

ID=37561086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008525132A Pending JP2009503093A (ja) 2005-08-01 2006-08-01 インスリン産生細胞の機能を保持する方法
JP2015002059A Pending JP2015091854A (ja) 2005-08-01 2015-01-08 インスリン産生細胞の機能を保持する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015002059A Pending JP2015091854A (ja) 2005-08-01 2015-01-08 インスリン産生細胞の機能を保持する方法

Country Status (10)

Country Link
EP (1) EP1915171B1 (enExample)
JP (2) JP2009503093A (enExample)
CN (1) CN101232899A (enExample)
AU (1) AU2006275424B2 (enExample)
BR (1) BRPI0614489A2 (enExample)
CA (1) CA2617226A1 (enExample)
DK (1) DK1915171T3 (enExample)
ES (1) ES2439455T3 (enExample)
MX (1) MX2008001643A (enExample)
WO (1) WO2007016600A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
SI2379100T1 (sl) * 2009-01-08 2015-02-27 Mannkind Corporation Zdravljenje hiperglikemije z GLP-1
MX2011009251A (es) * 2009-03-04 2011-11-18 Mannkind Corp Sistema mejorado de suministro de farmaco en polvo seco.
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
JP7109155B2 (ja) 2015-06-04 2022-07-29 キッコーマン株式会社 フラビン結合型グルコースデヒドロゲナーゼを用いたグルコースの測定方法
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor
CN110187123B (zh) * 2019-05-06 2022-07-22 天津医科大学总医院 一种糖尿病早期诊断生物标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975328A1 (en) * 1997-04-02 2000-02-02 Purdue Research Foundation Method for oral delivery of proteins
ES2395096T3 (es) * 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
GB0217382D0 (en) * 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
EP1605895A4 (en) * 2003-03-06 2011-08-24 Emisphere Tech Inc ORAL INSULIN THERAPIES AND PROTOCOL
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics

Similar Documents

Publication Publication Date Title
US20240181019A1 (en) Use of ultrarapid acting insulin
AU2016228157B2 (en) Use of ultrarapid acting insulin
AU2006275424B2 (en) Method of preserving the function of insulin-producing cells
US20250064898A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
Russell‐Jones et al. Recent advances in incretin‐based therapies
JP5788374B2 (ja) 糖尿病治療における優れた血糖コントロール
CN101027082A (zh) 降低2型糖尿病患者血清胰岛素原水平的方法
JP2007517892A5 (enExample)
Evans et al. Recent developments and emerging therapies for type 2 diabetes mellitus
JP2020510628A5 (enExample)
JP2020502151A5 (enExample)
US20210361746A1 (en) Composition and method for reducing hypoglycemia events in diabetes treatment
AU2013204281C1 (en) Use of ultrarapid acting insulin
CN116018156A (zh) 使用人类胰淀素类似物多肽对1型糖尿病患者提供卓越的血糖控制
HK1242994A1 (en) Use of ultrarapid acting insulin
HK1242994B (en) Use of ultrarapid acting insulin